Combined targeted therapy and immunotherapy in the treatment of advanced melanoma

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 997-999

  Wilmott, James S ^a,b   Scolyer, Richard A ^a,b,c   Long, Georgina V ^a,b,d   Hersey, Peter ^a,b,e  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

BRAF; BRAF mutation; CTLA 4; Immune response; Immunotherapy; Melanoma; Pathology; Targeted therapy; Tumor infiltrating lymphocytes

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF INHIBITOR; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; GRANZYME B; INTERLEUKIN 12; IPILIMUMAB; PD 1 ANTIBODY; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL DEATH; COMBINED TARGETED THERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG POTENTIATION; DRUG TARGETING; HUMAN; LYMPHOCYTE PROLIFERATION; MELANOMA; METASTASIS; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STROMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT;

EID: 84871390416     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19865     Document Type: Article

References (9)

1. Hodi FS, O'day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
2. Robert C, Thomas L, Bondarenko I, O'day S, MD JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621.
3. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29:1239- 46; PMID:21343559; http://dx.doi.org/10.1200/JCO.2010.32.4327.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAFV600E mutation. N Engl J Med 2011; 364:2507- 16; PMID:21639808; http://dx.doi.org/10.1056/ NEJMoa1103782.
5. Fedorenko IV, Paraiso KHT, Smalley KSM. Acquired and intrinsic BRAF inhibitor resistance in BRAFV600E mutant melanoma. Biochem Pharmacol 2011; 82:201- 9; PMID:21635872; http://dx.doi.org/10.1016/j.bcp.2011.05.015.
6. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma R, Thompson JF, et al. Selective BRAF inhibitors induce marked T cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18:1386-94; PMID:22156613; http://dx.doi.org/10.1158/1078-0432.CCR-11-2479.
7. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009; 14:364-75; PMID:19145485; http://dx.doi.org/10.1007/s10495-008-0303-9.
8. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancerimmune evasion in human melanoma cells. J Exp Med 2006; 203:1651-6; PMID:16801397; http://dx.doi.org/10.1084/jem.20051848.
9. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010; 107:4275-80; PMID:20160101; http://dx.doi.org/10.1073/pnas.0915174107.